



**COMPETITIVE
TECHNOLOGIES**

Unlocking the Potential of Innovation®

Investor Presentation
May, 2009

CTT
LISTED
NYSE Amex



Safe Harbor Statement

Statements about our future expectations are "forward-looking statements" and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2008, filed with the SEC on October 28, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.





Corporate Description

- Founded in 1968.
- Listed on NYSE Amex as CTT.
- CTT is a global leader in providing technology commercialization services for its clients.
- CTT is uniquely positioned to capitalize on factors driving the growth of the \$150 billion technology licensing market.
- Successfully licensed 500 technologies to over 400 organizations.





Areas of Specialization

CTT provides technology transfer services in:

- **Life Sciences** (including pharmaceuticals, biomedical devices, biotechnology, and clinical diagnostics)
- **Physical Sciences** (including materials, manufacturing and environmental technologies)
- **Digital/Electronic Technologies** (including Internet services, telecommunications and digital entertainment)
- **Nanotechnologies** (Nano Devices, Nano Tools, Nano Materials and Nano Biology)





The Tech Transfer Marketplace

Rapidly growing market for technology transfer services:

- Technology licensing market is currently over \$150 billion per year in fees and royalties from only \$3 billion in 1980; growing 15% per year.
- U.S. patent applications have grown from 100,000 in 1980 to over 465,000 in 2007.
- Global market for technology transfer driven by factors such as fast-moving technology market cycles, costly research and development, limited R & D budgets, and scarcity of R&D talent.
- Harvard Business Review estimates that 67% of Fortune companies have technology under exploited.
- Qualcomm receives over \$2.8 billion in licensing revenue from partners such as AT&T, SK Telecom and others.





Corporate Clientele

CTT has provided or obtained technology solutions for world-class companies including:

IBM 

JDSU 

Matsushita 

NEC 

Bayer  Bayer


Merck  MERCK

Roche Diagnostics 

TDK 

Pfizer 

SONY 

GE 

Abbott Laboratories 

Avery Dennison 

Biorad Laboratories 

Mitsubishi 

Toshiba 

Motorola 

Lucent 

***Clients include two Nobel Prize Winners:
Drs. Cech and MacDiarmid***





University Clientele

CTT has licensed technologies providing over \$100 million to world-class research institutions including:

Columbia University

Cornell University

Lehigh University

New York University

Princeton University

Texas A&M

University of Arizona

University of California

University of Chicago

University of Colorado

University of Connecticut

University of Illinois

University of Iowa

University of Virginia

University of Maryland

University of New Mexico

University of Pennsylvania

University of South Carolina

US universities spend \$30 Billion annually on Research and Development.





Current Business Model


CTT revenue is success-fee driven – we receive revenue and share it with our clients.

- Upfront Fees (Nanotechnology Bone Biomaterial)
- Royalties (Homocysteine Assay)
- Milestone Payments (Melanocortin Analogs)
- Shared Sales (Pain Therapy Device)





Emerging Market Integrative Medicine



Integrative Medicine:

- Reduce healthcare costs with wellness
- Regulated more like pharmaceuticals





Healthcare Initiatives Summary

Connecting Clinical Science to the Patient

- Pain therapy medical device
- Nanotechnology bone biomaterial
- Melanocortin analogs
- Non-invasive breast cancer screening device
- Lupus diagnostic assay
- Asthma bromide test
- Stress relieving device





Pain Therapy Medical Device

Device for non-invasive treatment of oncologic, neuropathic and drug-resistant pain:

- Impulses travel through nerve fibers to block/intercept pain signal transmission
- Employed in nine hospitals in Italy
- CE certified in Europe; Received FDA 510(k) authorization in U.S.
- GEOMC Co., Ltd. invested \$2.0 million designing and manufacturing this medical device.



Italian patent; US patent pending





Pain Therapy Medical Device

A paradigm technology shift:

- Revenue expected to dramatically exceed any other technology in CTT's 40-year history
- Medical device market \$240 billion annually
- Global pain management market expected to reach \$40 billion in 2010
- Distribution agreements signed in India, Korea, Malaysia and Bangladesh

Italian patent; US patent pending





Shared Sales Model

New Financial Business Models:

- Traditional Licensing Model
 - \$20,000 per device
 - 5% royalty license
 - Inventor Share - 3%
 - CTT Share - 2%
- New Shared Sales Model:
 - \$20,000 per device
 - CTT Share - 25%
 - Projected monthly revenue - \$1.5 million





Nanotechnology Bone Biomaterial



- Nanoparticle biomaterial for skeletal bone repair
- 2 issued US patents + PCT, more pending
- Soteira, Inc.: exclusive license for spinal repair
- Animal studies, 510(k) and IDE submissions
- Applications: broken bones/dental/veterinary
- Orthopedic market - \$10 billion





Melanocortin Analogs

- Synthetic analogs of α -MSH
- Applications for:
 - Male and female sexual disorder
 - Skin pigmentation - Clinuvel
 - Obesity
- Portfolio of 12 patents
- Over \$100 million invested in R & D
- Results from Phases I and II Clinical Trials

patented





Breast Cancer Screening Device

Non-invasive early-detection test for breast cancer:

- Generates an analysis that detects angiogenesis, the formation of new blood vessels that feed and nourish a tumor
- Adhesive pads embedded with hundreds of thermistors, micro-thermometers
- Schonberger's patent for world's first disposable thermometer is basis for the technology

patented





Lupus Diagnostic Assay

Solid-phase assay
quantifies antibodies
against dsDNA in Lupus
(SLE) patient sera:

- Cost effective
- Scalable testing platform
- Reimbursed by insurance

patented: US and foreign



Applications

- Diagnostics
- Monitoring
 - Disease progression
 - Therapeutic efficacy





Stress Relieving Device

Pocket-sized transmitter and goggles reduces stress and enhances concentration:

- Uses a synchronization of light and sound
- Micro-computer pre-programmed software control unit
- Stimulates beta, alpha, theta and delta brainwaves
- Non-invasive
- No side effects



patent pending





Breakthrough Technologies

- Solar Panels
- Video Image Compression
- Encryption Technology
- Crack Detection Paint





Financial Summary

- CTT expects revenue for the Pain Management Medical Device to exceed \$20 million per year, with limited related costs, as device attains mature market levels
- Operating costs reduced to about \$4 million per year, down from \$13 million in 2007, \$7 million in 2008
- CTT has operating loss-carryforwards of \$23 million
- \$5 million equity-put agreement with Fusion Capital; can be exercised at CTT option, if necessary, over the next two years



FINANCIALS

INCOME STATEMENT							
(\$000s)	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002
Revenues	\$1,193	\$4,167	\$5,188	\$14,174	\$8,022	\$3,319	\$2,596
Expenses	7159*	13,061	7,565	8,472	5,067	5,254	6,612
Net income/(loss)	(5,966)	(8,894)	(2,377)	5,702	2,955	(1,935)	(4,016)
Net income/(loss) \$/per share	(\$0.73)	(\$1.11)	(\$0.31)	\$0.78	\$0.46	(\$0.31)	(\$0.65)
Shares outstanding (000)	8,156	8,040	7,652	7,325	6,457	6,183	6,148

BALANCE SHEET							
(\$000s)	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002
Cash/Cash Equiv.	\$ 2,237	\$ 6,572	\$ 12,909	\$ 14,280	\$ 4,310	\$ 1,405	\$ 750
Other assets	874	3,141	5,508	5,161	2,371	1,548	5,650
Total Assets	\$ 3,111	\$ 9,713	\$ 18,417	\$ 19,441	\$ 6,681	\$ 2,953	\$ 6,400
Total Current and Non-Current Liabilities	\$ 1,518	\$ 2,114	\$ 3,963	\$ 5,333	\$ 1,742	\$ 1,783	\$ 3,407
Shareholders' Interest	1,593	7,599	14,454	14,108	4,939	1,170	2,993
Total Liabilities and Shareholders' Interest	\$ 3,111	\$ 9,713	\$ 18,417	\$ 19,441	\$ 6,681	\$ 2,953	\$ 6,400

* Current run rate for expenses about \$4 million per year





Profitable Growth

Many factors contribute to our improving profitable growth:

- A dynamic portfolio of new technologies
- Increased profits per commercial technology
- Utilize global relationships with manufacturers, distributors, governments and inventors
- Low operating costs – minimal overhead in technology transfer industry





THANK YOU.

Competitive Technologies, Inc.

www.competitivetech.net

